Loading…

ASPP1/2 positive patients with invasive breast cancers have good prognosis

Although the expression of ASPP family members in multiple tumors has been studied, especially in various cell lines of breast cancer (BC), but the expressions pattern of ASPP family members in invasive BC tissues are not clear. We studied the expression and expression pattern of ASPPs family member...

Full description

Saved in:
Bibliographic Details
Published in:Heliyon 2023-10, Vol.9 (10), p.e20613-e20613, Article e20613
Main Authors: Wang, Changsong, Li, Ke, An, Junling, Lv, Xuexia, Ma, Wenfeng, Wang, Yaxi, Meng, Nianlong, Yun, Tian, Zhao, Ting
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c492t-93ef1030cdfa6ce11420087d762ea826561c154a3386992d86ec0b5a87c124ac3
container_end_page e20613
container_issue 10
container_start_page e20613
container_title Heliyon
container_volume 9
creator Wang, Changsong
Li, Ke
An, Junling
Lv, Xuexia
Ma, Wenfeng
Wang, Yaxi
Meng, Nianlong
Yun, Tian
Zhao, Ting
description Although the expression of ASPP family members in multiple tumors has been studied, especially in various cell lines of breast cancer (BC), but the expressions pattern of ASPP family members in invasive BC tissues are not clear. We studied the expression and expression pattern of ASPPs family member in BCs, the relationship between ASPP family members and clinic-pathologic features of BCs was also analyzed. The results showed that the expression of ASPP1, ASPP2 and iASPP was observed on AE1/AE3+ tumor cells, and not on infiltrated lymphocytes and capillaries. The relationship between ASPP1 expression and pTNM stage has statistical difference (p<0.01). The relationship between expression of ASPP2 and SBR grade has statistical difference (p<0.05). The relationship between expression of iASPP and clinic-pathologic feature of patients has no statistical difference (p>0.05). The patients with positive expression of ASPP1 and the patients with negative expression of ASPP1 have statistical difference in 3-year survival rate and 5-year survival rate (χ2 = 4.49, P = 0.03; χ2 = 3.79, P = 0.048). Overall, our work demonstrated that the expression of ASPP1/2 contributes to predict the prognosis of patients with BC.
doi_str_mv 10.1016/j.heliyon.2023.e20613
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_effaeb55e7164aa18a313e5364445454</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2405844023078210</els_id><doaj_id>oai_doaj_org_article_effaeb55e7164aa18a313e5364445454</doaj_id><sourcerecordid>2883573061</sourcerecordid><originalsourceid>FETCH-LOGICAL-c492t-93ef1030cdfa6ce11420087d762ea826561c154a3386992d86ec0b5a87c124ac3</originalsourceid><addsrcrecordid>eNqFkU1rGzEQhkVpocHJTyjssRc7Gn2t9lRC6EdKoIG2ZzHWztoy69VWWrvk31dbmzY5BR0kXo0eZvQw9g74CjiY691qS314jMNKcCFXJLgB-YpdCMX10irFXz85v2VXOe8456CtaWp5wb7efH94gGtRjTGHKRypGnEKNEy5-h2mbRWGI-Y5XifCPFUeB08pV1ss2SbGthpT3Azlcb5kbzrsM12d9wX7-enjj9svy_tvn-9ub-6XXjViWjaSOuCS-7ZD4wlACc5t3dZGEFphtAEPWqGUpcVGtNaQ52uNtvYgFHq5YHcnbhtx58YU9pgeXcTg_gYxbRymKfieHHUd0lprqsEoRLAoQZKWRimlyyqsDyfWeFjvqfVl8IT9M-jzmyFs3SYeHXDd1BZmwvszIcVfB8qT24fsqe9xoHjIToKWtZJg6xdLhbVS13IWuGD6VOpTzDlR968l4G727nbu7N3N3t3J-_95qAg4Bkou-2LTUxsS-an8UHiB8AdTxbih</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2883573061</pqid></control><display><type>article</type><title>ASPP1/2 positive patients with invasive breast cancers have good prognosis</title><source>ScienceDirect</source><source>PubMed (Medline)</source><creator>Wang, Changsong ; Li, Ke ; An, Junling ; Lv, Xuexia ; Ma, Wenfeng ; Wang, Yaxi ; Meng, Nianlong ; Yun, Tian ; Zhao, Ting</creator><creatorcontrib>Wang, Changsong ; Li, Ke ; An, Junling ; Lv, Xuexia ; Ma, Wenfeng ; Wang, Yaxi ; Meng, Nianlong ; Yun, Tian ; Zhao, Ting</creatorcontrib><description>Although the expression of ASPP family members in multiple tumors has been studied, especially in various cell lines of breast cancer (BC), but the expressions pattern of ASPP family members in invasive BC tissues are not clear. We studied the expression and expression pattern of ASPPs family member in BCs, the relationship between ASPP family members and clinic-pathologic features of BCs was also analyzed. The results showed that the expression of ASPP1, ASPP2 and iASPP was observed on AE1/AE3+ tumor cells, and not on infiltrated lymphocytes and capillaries. The relationship between ASPP1 expression and pTNM stage has statistical difference (p<0.01). The relationship between expression of ASPP2 and SBR grade has statistical difference (p<0.05). The relationship between expression of iASPP and clinic-pathologic feature of patients has no statistical difference (p>0.05). The patients with positive expression of ASPP1 and the patients with negative expression of ASPP1 have statistical difference in 3-year survival rate and 5-year survival rate (χ2 = 4.49, P = 0.03; χ2 = 3.79, P = 0.048). Overall, our work demonstrated that the expression of ASPP1/2 contributes to predict the prognosis of patients with BC.</description><identifier>ISSN: 2405-8440</identifier><identifier>EISSN: 2405-8440</identifier><identifier>DOI: 10.1016/j.heliyon.2023.e20613</identifier><language>eng</language><publisher>Elsevier Ltd</publisher><subject>breast neoplasms ; breasts ; family ; prognosis ; survival rate</subject><ispartof>Heliyon, 2023-10, Vol.9 (10), p.e20613-e20613, Article e20613</ispartof><rights>2023 The Authors</rights><rights>2023 The Authors 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c492t-93ef1030cdfa6ce11420087d762ea826561c154a3386992d86ec0b5a87c124ac3</cites><orcidid>0000-0001-5686-7912</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597814/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S2405844023078210$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,3536,27903,27904,45759,53769,53771</link.rule.ids></links><search><creatorcontrib>Wang, Changsong</creatorcontrib><creatorcontrib>Li, Ke</creatorcontrib><creatorcontrib>An, Junling</creatorcontrib><creatorcontrib>Lv, Xuexia</creatorcontrib><creatorcontrib>Ma, Wenfeng</creatorcontrib><creatorcontrib>Wang, Yaxi</creatorcontrib><creatorcontrib>Meng, Nianlong</creatorcontrib><creatorcontrib>Yun, Tian</creatorcontrib><creatorcontrib>Zhao, Ting</creatorcontrib><title>ASPP1/2 positive patients with invasive breast cancers have good prognosis</title><title>Heliyon</title><description>Although the expression of ASPP family members in multiple tumors has been studied, especially in various cell lines of breast cancer (BC), but the expressions pattern of ASPP family members in invasive BC tissues are not clear. We studied the expression and expression pattern of ASPPs family member in BCs, the relationship between ASPP family members and clinic-pathologic features of BCs was also analyzed. The results showed that the expression of ASPP1, ASPP2 and iASPP was observed on AE1/AE3+ tumor cells, and not on infiltrated lymphocytes and capillaries. The relationship between ASPP1 expression and pTNM stage has statistical difference (p<0.01). The relationship between expression of ASPP2 and SBR grade has statistical difference (p<0.05). The relationship between expression of iASPP and clinic-pathologic feature of patients has no statistical difference (p>0.05). The patients with positive expression of ASPP1 and the patients with negative expression of ASPP1 have statistical difference in 3-year survival rate and 5-year survival rate (χ2 = 4.49, P = 0.03; χ2 = 3.79, P = 0.048). Overall, our work demonstrated that the expression of ASPP1/2 contributes to predict the prognosis of patients with BC.</description><subject>breast neoplasms</subject><subject>breasts</subject><subject>family</subject><subject>prognosis</subject><subject>survival rate</subject><issn>2405-8440</issn><issn>2405-8440</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNqFkU1rGzEQhkVpocHJTyjssRc7Gn2t9lRC6EdKoIG2ZzHWztoy69VWWrvk31dbmzY5BR0kXo0eZvQw9g74CjiY691qS314jMNKcCFXJLgB-YpdCMX10irFXz85v2VXOe8456CtaWp5wb7efH94gGtRjTGHKRypGnEKNEy5-h2mbRWGI-Y5XifCPFUeB08pV1ss2SbGthpT3Azlcb5kbzrsM12d9wX7-enjj9svy_tvn-9ub-6XXjViWjaSOuCS-7ZD4wlACc5t3dZGEFphtAEPWqGUpcVGtNaQ52uNtvYgFHq5YHcnbhtx58YU9pgeXcTg_gYxbRymKfieHHUd0lprqsEoRLAoQZKWRimlyyqsDyfWeFjvqfVl8IT9M-jzmyFs3SYeHXDd1BZmwvszIcVfB8qT24fsqe9xoHjIToKWtZJg6xdLhbVS13IWuGD6VOpTzDlR968l4G727nbu7N3N3t3J-_95qAg4Bkou-2LTUxsS-an8UHiB8AdTxbih</recordid><startdate>20231001</startdate><enddate>20231001</enddate><creator>Wang, Changsong</creator><creator>Li, Ke</creator><creator>An, Junling</creator><creator>Lv, Xuexia</creator><creator>Ma, Wenfeng</creator><creator>Wang, Yaxi</creator><creator>Meng, Nianlong</creator><creator>Yun, Tian</creator><creator>Zhao, Ting</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-5686-7912</orcidid></search><sort><creationdate>20231001</creationdate><title>ASPP1/2 positive patients with invasive breast cancers have good prognosis</title><author>Wang, Changsong ; Li, Ke ; An, Junling ; Lv, Xuexia ; Ma, Wenfeng ; Wang, Yaxi ; Meng, Nianlong ; Yun, Tian ; Zhao, Ting</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c492t-93ef1030cdfa6ce11420087d762ea826561c154a3386992d86ec0b5a87c124ac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>breast neoplasms</topic><topic>breasts</topic><topic>family</topic><topic>prognosis</topic><topic>survival rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Changsong</creatorcontrib><creatorcontrib>Li, Ke</creatorcontrib><creatorcontrib>An, Junling</creatorcontrib><creatorcontrib>Lv, Xuexia</creatorcontrib><creatorcontrib>Ma, Wenfeng</creatorcontrib><creatorcontrib>Wang, Yaxi</creatorcontrib><creatorcontrib>Meng, Nianlong</creatorcontrib><creatorcontrib>Yun, Tian</creatorcontrib><creatorcontrib>Zhao, Ting</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ: Directory of Open Access Journals</collection><jtitle>Heliyon</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Changsong</au><au>Li, Ke</au><au>An, Junling</au><au>Lv, Xuexia</au><au>Ma, Wenfeng</au><au>Wang, Yaxi</au><au>Meng, Nianlong</au><au>Yun, Tian</au><au>Zhao, Ting</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ASPP1/2 positive patients with invasive breast cancers have good prognosis</atitle><jtitle>Heliyon</jtitle><date>2023-10-01</date><risdate>2023</risdate><volume>9</volume><issue>10</issue><spage>e20613</spage><epage>e20613</epage><pages>e20613-e20613</pages><artnum>e20613</artnum><issn>2405-8440</issn><eissn>2405-8440</eissn><abstract>Although the expression of ASPP family members in multiple tumors has been studied, especially in various cell lines of breast cancer (BC), but the expressions pattern of ASPP family members in invasive BC tissues are not clear. We studied the expression and expression pattern of ASPPs family member in BCs, the relationship between ASPP family members and clinic-pathologic features of BCs was also analyzed. The results showed that the expression of ASPP1, ASPP2 and iASPP was observed on AE1/AE3+ tumor cells, and not on infiltrated lymphocytes and capillaries. The relationship between ASPP1 expression and pTNM stage has statistical difference (p<0.01). The relationship between expression of ASPP2 and SBR grade has statistical difference (p<0.05). The relationship between expression of iASPP and clinic-pathologic feature of patients has no statistical difference (p>0.05). The patients with positive expression of ASPP1 and the patients with negative expression of ASPP1 have statistical difference in 3-year survival rate and 5-year survival rate (χ2 = 4.49, P = 0.03; χ2 = 3.79, P = 0.048). Overall, our work demonstrated that the expression of ASPP1/2 contributes to predict the prognosis of patients with BC.</abstract><pub>Elsevier Ltd</pub><doi>10.1016/j.heliyon.2023.e20613</doi><orcidid>https://orcid.org/0000-0001-5686-7912</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2405-8440
ispartof Heliyon, 2023-10, Vol.9 (10), p.e20613-e20613, Article e20613
issn 2405-8440
2405-8440
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_effaeb55e7164aa18a313e5364445454
source ScienceDirect; PubMed (Medline)
subjects breast neoplasms
breasts
family
prognosis
survival rate
title ASPP1/2 positive patients with invasive breast cancers have good prognosis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T02%3A46%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ASPP1/2%20positive%20patients%20with%20invasive%20breast%20cancers%20have%20good%20prognosis&rft.jtitle=Heliyon&rft.au=Wang,%20Changsong&rft.date=2023-10-01&rft.volume=9&rft.issue=10&rft.spage=e20613&rft.epage=e20613&rft.pages=e20613-e20613&rft.artnum=e20613&rft.issn=2405-8440&rft.eissn=2405-8440&rft_id=info:doi/10.1016/j.heliyon.2023.e20613&rft_dat=%3Cproquest_doaj_%3E2883573061%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c492t-93ef1030cdfa6ce11420087d762ea826561c154a3386992d86ec0b5a87c124ac3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2883573061&rft_id=info:pmid/&rfr_iscdi=true